• OPEN AN ACCOUNT
Indian Indices
Sensex
83,919.71 897.96
( 1.08%)
Global Indices
Nasdaq
48,502.41 -615.65
(-1.25%)
Dow Jones
6,987.82 -209.01
(-2.90%)
Hang Seng
56,657.02 -2,787.19
(-4.69%)
Nikkei 225
10,369.59 -83.09
(-0.79%)
Forex
USD-INR
93.34 -0.08
(-0.09%)
EUR-INR
102.47 -0.06
(-0.06%)
GBP-INR
122.55 -0.48
(-0.39%)
JPY-INR
0.58 0.00
(-0.32%)

EQUITY - MARKET SCREENER

Varanium Cloud Ltd
Industry :  Computers - Software - Medium / Small
BSE Code
ISIN Demat
Book Value()
535478
INE0JOO01021
58.6151128
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
CLOUD
0.22
23.7
EPS(TTM)
Face Value()
Div & Yield %
26.68
5
42.41
 

Lupin announces launch of its biosimilar Ranibizumab in Europe
Nov 12,2026

Lupin today announced that its commercial partner, Sandoz has launched Ranluspec, Lupin's biosimilar Ranibizumab, across Europe, excluding Germany.

The launch follows the European Commission approval of Ranluspec in vial and pre-filled syringe presentations and marks an important step in expanding access to high-quality biologic treatment options for retinal diseases.

Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A. The indications of Ranluspec encompass the treatment of patients with neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, proliferative diabetic retinopathy, and choroidal neovascularization.